Novozymes stock
NSIS-B.COCPHNovozymes A/S, Basic MaterialsISIN DK0060336014
53Score 53 out of 100, Neutral
Price and trend
73 / 100
Price history
+6.9% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 35).
The price is 6.2% below its 52-week high. Largest decline in 20 years: 53% (August 2007 to October 2008).
Chart figures for advanced users
- SMA 50$65.82
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$60.39
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)35
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$50.70
- The lowest closing price of the last twelve months.
- Resistance$71.37
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Novozymes A/S belongs to the Chemicals (Specialty) industry (Denmark) and, with a market value of $27.62B, is number 10 of 106 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.6B (up 8.5% year on year) and earnings of $646.2M (up 90.8%).
- MEQIRI Score 53 out of 100 (Neutral): rank 284 of 461 in Basic Materials, median 57.
Show more
- The P/E is 41.7 (Chemicals (Specialty) median 24.4, own median of recent years 33.6).
- Our model puts fair value at $51.99, with the price 29% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 25 years.
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 80
- High marginNet margin 15.6% over the last 12 months, Chemicals (Specialty) median 4.9%.Profitability 58
Weaknesses
- DilutionShare count up 48% since 2020.Capital allocation 30
- Earnings per share fallingDown 34.1% a year since 2020.Growth 5
- Revenue shrinkingRevenue down 21.6% a year since 2020.Growth 5
Its standout strengths are stability and fundamentals, while valuation and growth hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 54 to 53.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
What lowers it
- low growth grade (crashed less often in the backtest)
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $39.99 and expensive above $74.27 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $64.72 (cash-flow model) and $39.26 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $46.66, at 6.1% it would be $59.98.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (24.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.5% on the twelve months before. Revenue has changed sharply in recent years: $4.6B in 2025 after $19.83B in 2023.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 54%, operating 21%, net 14%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 5 Nov 2026EPS reported 4.09 (expected 4.94)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 4.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- 2.05−4.3%
- Revenue
- $4.97B0.0%
- Earnings per share
- 2.3−4.2%
- Revenue
- $5.36B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +9.2%The 2026 organic sales growth guidance was raised to 7% to 8% and the adjusted EBITDA margin is now expected at the higher end of 37% to 38%.
“With a stronger sales outlook, we now also expect the adjusted EBITDA margin to be at the higher end of the 37% to 38% range.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 20 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Novozymes
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
461 rated companies in Basic Materials
- This company
- 53
- Sector median
- 57
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- GivaudanGIVN.SW $45.33B73
- SikaSIKA.SW $37.34B68
- Wanhua Chemical Group600309.SS $32.36B59
- dsm-firmenichDSFIR.AS $28.47B57
- PPG IndustriesPPG $27.03B70
- Asian PaintsASIANPAINT.NS $25.84B66
- Ems-Chemie HoldingEMSN.SW $23.81B74
- LyondellBasell IndustriesLYB $20.65B63
ETFs that hold Novozymes
Held by 88 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi Global Bioenergy UCITS ETF EUR AccWDNR | 7.78% | 0.35% | €146.72M |
| State Street SPDR MSCI Europe Materials UCITS ETFSPYP | 3.33% | 0.18% | €110.91M |
| Xtrackers MSCI Europe Materials Screened UCITS ETF 1CDXSC | 3.16% | 0.17% | €67.38M |
Show 5 more
| Xtrackers MSCI Nordic UCITS ETF 1DXDN0 | 1.67% | 0.30% | €1.19B |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 1.20% | 0.46% | €722.41M |
| Xtrackers MSCI World Materials UCITS ETF 1CXDWM | 0.84% | 0.25% | €720.77M |
| JPMorgan Europe Research Enhanced Index Equity Active UCITS ETFJREE | 0.83% | 0.25% | €2.95B |
| iShares Edge MSCI Europe Minimum Volatility UCITS ETFEUN0 | 0.77% | 0.25% | €991.48M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.